Details

Autor(en) / Beteiligte

• Yan, Yibing
• Wongchenko, Matthew J.
• Robert, Caroline
• Larkin, James
• Ascierto, Paolo A.
• Dréno, Brigitte
• Maio, Michele
• Garbe, Claus
• Chapman, Paul B.
• Sosman, Jeffrey A.
• Shi, Zhen
• Koeppen, Hartmut
• Hsu, Jessie J.
• Chang, Ilsung
• Caro, Ivor
• Rooney, Isabelle
• McArthur, Grant A.
• Ribas, Antoni

Titel

Genomic features of exceptional response in vemurafenib ± cobimetinib–treated patients with BRAFV600-mutated metastatic melanoma

Ist Teil von

• Clinical cancer research, 2019-03, Vol.25 (11), p.3239-3246

Erscheinungsjahr

2019

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Our exploratory analysis of baseline BRAF V600 -mutated melanoma samples from the coBRIM study aimed to identify genetic characteristics of patients with a complete response or no response to combined BRAF and MEK inhibition with vemurafenib and cobimetinib. No individual mutation was identified as a population-wide driver of exceptional response, but certain gene expression signatures were found to distinguish the two extremes of response. Melanomas from patients with complete response possessed higher preexisting tumor immunity features, while those from patients with rapid progression had a keratin signature similar to one previously associated with poor prognosis. These findings suggest that enriched immune infiltration of melanomas may be a shared feature of favorable response to both targeted and immune therapies, and distinct from features of innate resistance to immune and targeted therapies. We anticipate these findings could assist in optimization of treatment selection for patients with BRAF V600 -mutated metastatic melanoma.